1,408 reports of this reaction
1.9% of all PIOGLITAZONE reports
#10 most reported adverse reaction
DYSPNOEA is the #10 most commonly reported adverse reaction for PIOGLITAZONE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 1,408 FDA adverse event reports linking PIOGLITAZONE to DYSPNOEA. This represents approximately 1.9% of all 74,368 adverse event reports for this drug.
PIOGLITAZONE has an overall safety score of 85 out of 100. Patients taking PIOGLITAZONE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for PIOGLITAZONE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for PIOGLITAZONE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,408 FDA reports for PIOGLITAZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.9% of all adverse event reports for PIOGLITAZONE, making it a notable side effect.
If you experience dyspnoea while taking PIOGLITAZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.